Rosuvastatin is a commonly prescribed medication to lower high cholesterol levels.
However, a recent study from Johns Hopkins University has found potential damaging effects of rosuvastatin, particularly at higher doses, on the kidneys.
This study highlights the importance of understanding the risks associated with this medication.
Rosuvastatin belongs to a group of medications called statins, which are effective in reducing high cholesterol.
Before its approval by the U.S. Food and Drug Administration, reports linked rosuvastatin with signs of kidney damage, such as blood in the urine (hematuria) and protein in the urine (proteinuria).
However, limited post-marketing surveillance exists to assess the real-world risk of these kidney complications.
The Study
In this study, researchers analyzed electronic health record data for 152,101 new users of rosuvastatin and 795,799 new users of another statin called atorvastatin between 2011 and 2019.
The aim was to evaluate the occurrence of hematuria and proteinuria in these individuals over a follow-up period of three years.
Findings
The researchers observed hematuria in 2.9% of patients and proteinuria in 1.0% of patients.
When comparing rosuvastatin with atorvastatin, rosuvastatin use was associated with an 8% higher risk of hematuria, a 17% higher risk of proteinuria, and a 15% higher risk of kidney failure requiring replacement therapy, such as dialysis or transplantation.
Dose-Dependent Risks
The risks of hematuria and proteinuria were found to be higher with higher doses of rosuvastatin.
Interestingly, among patients with advanced kidney disease, 44% were prescribed a higher dose of rosuvastatin than recommended by the U.S. Food and Drug Administration for individuals with poor kidney function.
Implications and Recommendations
The study indicates a higher risk of hematuria, proteinuria, and kidney failure associated with rosuvastatin use.
Despite similar heart benefits between rosuvastatin and atorvastatin, the potential risks, especially with high doses of rosuvastatin, may outweigh the benefits—particularly for individuals with advanced kidney disease.
The findings emphasize the importance of carefully considering the risks and benefits of rosuvastatin use, especially for those with existing kidney conditions.
The study sheds light on potential kidney risks associated with rosuvastatin use, particularly at higher doses.
As with any medication, it is crucial for healthcare providers and patients to have open discussions about the potential benefits and risks.
Further research and monitoring are necessary to better understand the long-term effects of rosuvastatin on kidney health.
If you care about kidney health, please read studies about the drug that prevents kidney failure in diabetes, and drinking coffee could help reduce the risk of kidney injury.
For more information about health, please see recent studies that blueberries strongly benefit people with metabolic syndrome, and common painkillers may harm the heart, kidneys, and more.
Copyright © 2023 Knowridge Science Report. All rights reserved.
